Corium International (NASDAQ:CORI) has been assigned a $14.00 target price by HC Wainwright in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 14.94% from the company’s previous close.
Other equities research analysts have also issued reports about the stock. BidaskClub upgraded shares of Corium International from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Needham & Company LLC boosted their target price on shares of Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, November 20th. Jefferies Group set a $10.00 target price on shares of Corium International and gave the stock a “buy” rating in a research report on Sunday, October 29th. Cantor Fitzgerald restated a “buy” rating and set a $14.00 target price on shares of Corium International in a research report on Friday, December 22nd. Finally, ValuEngine upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.86.
Shares of Corium International (CORI) traded up $0.17 during midday trading on Friday, hitting $12.18. 207,713 shares of the company’s stock traded hands, compared to its average volume of 196,123. The stock has a market cap of $441.51, a price-to-earnings ratio of -7.76 and a beta of 1.59. Corium International has a 52 week low of $2.77 and a 52 week high of $13.93. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 2.41.
In other news, major shareholder Healthcare Master Fun Broadfin sold 500,000 shares of Corium International stock in a transaction on Friday, November 17th. The stock was sold at an average price of $10.96, for a total transaction of $5,480,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of the business’s stock in a transaction dated Thursday, January 18th. The shares were purchased at an average cost of $12.54 per share, with a total value of $6,395,400.00. The disclosure for this purchase can be found here. Insiders own 30.80% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its stake in shares of Corium International by 33.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 22,285 shares during the last quarter. TIAA CREF Investment Management LLC acquired a new position in Corium International in the 2nd quarter valued at about $411,000. Teachers Advisors LLC acquired a new position in Corium International in the 2nd quarter valued at about $272,000. New York State Common Retirement Fund acquired a new position in Corium International in the 2nd quarter valued at about $158,000. Finally, California State Teachers Retirement System acquired a new position in Corium International in the 2nd quarter valued at about $263,000. 89.15% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/10/corium-international-cori-pt-set-at-14-00-by-hc-wainwright.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.